Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
BioLineRx, Ltd. |
---|---|
Information provided by: | BioLineRx, Ltd. |
ClinicalTrials.gov Identifier: | NCT00480246 |
This is a single dose, open-label, 2-panel (Parts A and B) PET study investigating the degree of occupancy of dopamine 2 receptors (D2_RO) in the human brain after single oral doses of BL-1020 or Perphenazine (Trilafon®, hereafter called Perphenazine) in healthy male subjects. In Part A the D2_RO is investigated for the study compound BL-1020 and in Part B the D2_RO of BL-1020 is compared to the D2_RO of Perphenazine, a reference compound.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: BL 1020 Drug: Perphenazine |
Phase I |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Active Control, Parallel Assignment |
Ages Eligible for Study: | 21 Years to 35 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | BL- 1020.02 |
Study First Received: | May 28, 2007 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00480246 History of Changes |
Health Authority: | United States: Food and Drug Administration; Sweden: Medical Products Agency |
receptor oocupancy |
Neurotransmitter Agents Tranquilizing Agents Dopamine Perphenazine Raclopride |
Psychotropic Drugs Central Nervous System Depressants Dopamine Agents Healthy Antipsychotic Agents |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Perphenazine Therapeutic Uses Dopamine Agents Central Nervous System Agents |